Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials
José M. Garcia(University of Washington), John Friend(Helsinn Therapeutics (United States)), Elizabeth Manning Duus(Johns Hopkins University), Ying Yan(Chinese Academy of Medical Sciences & Peking Union Medical College), Charles D. Graham, Suzan Allen(Helsinn Therapeutics (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders)
Cited by 218
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
|The Lancet Oncology|2013|387